Reading time: 13 minutes
China is one of the largest assisted reproduction markets in the world. The National Health Commission has licensed more than 600 ART (assisted reproductive technology) institutions, and over one million IVF / ICSI cycles are performed in China each year [1]. The clinical pregnancy rates at the leading Chinese reproductive centres sit in the same range as top US and European centres, while prices are typically 25–35% of US levels. But IVF in China is governed by tight legal and ethical rules — not every patient is legally eligible to do IVF in China — and this is the question every international patient needs to answer before any hospital comparison. This article works through eligibility, the procedures actually permitted, the timeline, the leading hospitals, and real costs.
1. The Most Important Thing First: Legal Eligibility for IVF in China
The governing framework is the National Health Commission’s Administrative Measures on Human Assisted Reproductive Technology together with its ethical principles [2]. As of 2026, an international patient seeking IVF in China must meet all of the following:
- A married, opposite-sex couple — you must provide a marriage certificate, and a foreign marriage certificate must be authenticated through your country’s foreign-affairs ministry or via Hague Apostille, plus consular legalisation or notarised translation as required.
- A documented medical indication for infertility — clear infertility diagnosis on the female or male side.
- Both spouses physically present at key procedure points (egg retrieval, embryo transfer).
What China currently does not permit:
- IVF for single women — not allowed
- IVF for same-sex couples — not allowed
- Surrogacy — any form of surrogacy is expressly prohibited [3]
- Anonymous third-party egg donation — commercial egg donation is prohibited; only anonymous internal donation of surplus eggs from another patient’s own IVF cohort is allowed under strict conditions
- Anonymous sperm donation — only through the roughly 30 state-licensed human sperm banks, and only for patients with specific medical indications
- Sex selection — prohibited except for clearly indicated medical reasons (X-linked genetic disease, etc.)
- PGT for non-medical purposes — must be supported by a documented genetic disease or recurrent pregnancy loss indication
If you fall into any of the prohibited categories above, China is not a viable destination for you. We strongly suggest disclosing your situation honestly rather than attempting to circumvent the rules — the risks are high and the outcome cannot be delivered.
2. What Is Allowed in China
- Standard IVF / ICSI / intracytoplasmic sperm injection
- Embryo freezing and frozen embryo transfer (FET)
- PGT-A (aneuploidy screening) — requires indications such as recurrent pregnancy loss, advanced maternal age, or multiple failed IVF cycles
- PGT-M (monogenic disease diagnosis) — clear genetic disease family history
- PGT-SR (structural abnormality screening) — chromosomal translocations and similar
- ICSI for mild to moderate male factor infertility
- A small number of centres offer IVM (in-vitro maturation)
3. Representative Leading NHC-Licensed Reproductive Centres
Chinese ART institutions are licensed by the National Health Commission, with more than 600 licensed institutions nationwide [1]. The list below shows the centres with the largest publicly reported academic profile and cycle volume — this is a reference list, not a ranking:
| Hospital | City | Notes |
|---|---|---|
| Peking University Third Hospital Reproductive Centre | Beijing | One of the earliest and largest by volume; led by Professor Qiao Jie’s team |
| CITIC-Xiangya Reproductive and Genetic Specialty Hospital | Changsha | Founded by Professor Lu Guangxiu; PGT leadership |
| Reproductive Hospital affiliated to Shandong University | Jinan | Led by Professor Chen Zi-Jiang’s team |
| Renji Hospital, Shanghai Jiao Tong University School of Medicine | Shanghai | High volume in East China |
| Obstetrics & Gynecology Hospital of Fudan University | Shanghai | |
| First Affiliated Hospital of Sun Yat-sen University Reproductive Centre | Guangzhou | Leading centre in South China |
| Women’s Hospital, Zhejiang University School of Medicine | Hangzhou | |
| Jiangsu Province Hospital Reproductive Centre | Nanjing |
Important warning: China has a substantial grey market of unauthorised “fertility assistance” agencies. Only consider institutions formally licensed by the National Health Commission and verifiable on the NHC’s public registry. We work only with licensed institutions.
4. Clinical Data and Success Rates
The China Assisted Reproductive Data Registry (CARDR) shows that compliant reporting centres achieve clinical pregnancy rates of roughly 40–55% per transfer cycle and live birth rates of 35–45% for women under 35. For women aged 40 or above, live birth rates fall materially to 10–20% [4][5]. These figures are in the same range as US SART reports and European ESHRE reports [6][7].
To be plain: success rates depend on age, ovarian reserve, male factors, and comorbidities far more than on the choice of clinic. Any institution promising you “guaranteed success” or a “95% success rate” — walk away.
5. Typical Process and Timeline
A complete IVF cycle typically takes 4 to 6 weeks:
- Initial consultation and evaluation: 2–5 days (both spouses present)
- Ovarian stimulation: 8–14 days (daily subcutaneous injections plus multiple ultrasounds and blood tests)
- Egg retrieval and fertilisation: retrieval day plus 3–5 days of lab culture
- Fresh embryo transfer or whole-cohort cryopreservation: transfer 3–5 days after retrieval (fresh) or freeze all
- Luteal support and waiting: pregnancy test 14 days after transfer
- Frozen embryo transfer (FET) cycle: can be performed in the following menstrual cycle or later; each FET requires 2–3 weeks in China
Typical in-China duration for international patients:
- Single complete fresh cycle: about 4–6 weeks (consecutive in China)
- Egg retrieval, return home, later FET: first trip about 3 weeks, second trip about 2 weeks
6. Real Costs (USD, 1 USD = 6.5 RMB)
| Item | Leading public centre | High-end private centre |
|---|---|---|
| Complete IVF cycle (incl. stimulation drugs, retrieval, ICSI, fresh transfer) | 5,500–9,000 | 12,000–20,000 |
| Whole-cohort cryopreservation | base + 300–600 | base + 500–1,200 |
| Single frozen embryo transfer (FET) | 1,200–2,500 | 3,500–6,500 |
| PGT-A (per embryo tested) | 500–800 | 800–1,500 |
| PGT-M | total 3,000–6,000 (custom probe) | 5,000–10,000 |
| Male sperm analysis and processing | 200–500 | 500–1,500 |
| International patient translation coordination (self-arranged) | 100–300 per day | usually included in package |
US reference:
- A complete IVF cycle in the US typically runs USD 15,000–25,000, plus PGT USD 4,000–7,000 [8]
- European reference: roughly USD 6,000–12,000
The Chinese cost advantage comes mostly from labour and locally manufactured lab consumables. Clinical and laboratory technique at the leading Chinese centres is comparable to top US and European centres.
7. Important Notes Specific to International Patients
- Marriage certificate authentication takes time — Hague Apostille plus translation and notarisation typically takes 2–6 weeks; start early
- The female partner must be physically present at least twice — egg retrieval and embryo transfer cannot be delegated
- The male partner must be physically present to provide a sperm sample, at minimum on the day of egg retrieval
- Stimulation drug logistics — most are subcutaneous injections, some require refrigeration; check your home country’s customs limits if bringing supplies in
- Cross-border embryo transport — China currently does not permit cross-border transport of embryos back to your home country for storage; this is a legal red line [9]
- Insurance — most international medical policies do not cover IVF; check your policy and any riders
8. Continuing Care After Returning Home
- After pregnancy is confirmed, build your obstetric care file in your home country
- The Chinese reproductive centre can issue an English summary (retrieval, transfer, medications, embryo information) for your home physician
- Luteal support medications (progesterone, oestrogen) are generally available at home
9. What MedCareInChina Can and Cannot Do on the IVF Pathway
Our two products are Remote Consultation and In-China Accompanied Care. In the IVF context:
- Remote Consultation: a USD 800 single-expert remote consultation with a reproductive medicine physician at one of the leading centres above, who reviews your records and gives an initial assessment of suitability for treatment in China and a recommended approach
- In-China Accompanied Care: hospital accompaniment, translation, and coordination at key milestones (retrieval, transfer) during your time in China
What we do not do:
- We do not handle marriage certificate authentication, notarisation, or translation — please complete these in your home country
- We do not file visa applications (see Article #45)
- We do not participate in or facilitate any surrogacy, commercial egg sale, cross-border embryo transport, or any other prohibited activity
- We do not guarantee treatment outcomes
10. Action Checklist
- Self-assess whether you meet Chinese IVF legal eligibility (married opposite-sex couple plus medical indication)
- Complete Hague Apostille / consular authentication and notarised translation of your marriage certificate in your home country
- Prepare both spouses’ prior fertility evaluation (semen analysis, AMH, hormone panel, ultrasound)
- Engage a remote consultation with a Chinese reproductive physician to assess suitability and recommended approach
- Confirm visa (S2; both patient and spouse apply separately)
- Arrange 4–6 weeks in China (fresh cycle) or split trips (frozen cycle)
Sources
[1] National Health Commission of the People’s Republic of China — Registry of licensed human assisted reproductive technology institutions (publicly searchable): http://www.nhc.gov.cn/ [2] National Health Commission — Administrative Measures on Human Assisted Reproductive Technology: http://www.nhc.gov.cn/ [3] National Health Commission — Ethical Principles for Human Assisted Reproductive Technology and Human Sperm Banks (including the prohibition of surrogacy) [4] Chinese Society of Reproductive Medicine — China Assisted Reproductive Technology Data Report: https://www.csrm.org.cn/ [5] CARDR (China Assisted Reproductive Data Registry) annual data [6] Society for Assisted Reproductive Technology (SART) — National Summary Report, USA: https://www.sart.org/ [7] ESHRE — European IVF Monitoring Consortium annual report: https://www.eshre.eu/ [8] American Society for Reproductive Medicine — Patient cost benchmarks: https://www.asrm.org/ [9] General Administration of Customs of the PRC — Regulations on inbound/outbound biological products and human reproductive cells: http://www.customs.gov.cn/